Tagged with Biotech

GSK KaNDy Therapeutics, a UK-based biotech has raised £25 million to finance the Phase 2b trial of their breakthrough product in Women’s Health. Our investors and the KaNDy management team are united by the common belief that NT-814 has the potential to be a transformational treatment for the millions of women worldwide…

Hong Kong Professor Hon-Ming Lam, a renowned scientist specializing in soybean genomics, shares his passion for his research, the importance of soybeans to China’s future environmental and growth sustainability, his insights on Hong Kong’s ambition to become an innovation and technology hub, and his perspective on how government, industry and academics should…

Hong Kong Professor Justin Wu, chief operating officer of the Chinese University of Hong Kong (CUHK) Medical Center, shares his professional background and interest in gastroenterology, his insights into the research and commercialization environment in Hong Kong, and his hope for government, industry and academia to work together to propel Hong Kong…

UK Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid presence in the development and manufacturing of new advanced treatments. He further explains how the company has been able to…

UK Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and private sector and Cobra Biologics’ ambitious plans for 2022. Can you please introduce Cobra Biologics to our international readers? “The…

UK Adaptimmune, a British-based biotech company born out of the University of Oxford has a solid research base in the UK and manufactures its T-Cells in the US. Its CEO, James Noble, shares Adaptimmune’s story and explains why regulatory support is essential in a field as complex and novel as T-Cell…

UK Recently appointed as general manager & vice president of Gilead’s UK and Ireland operations, Hilary Hutton-Squire highlights the uniqueness of the UK’s healthcare system, its expertise in life sciences and global leadership in clinical trials. To her, the UK has to maintain its core differentiators, such as a health technology…

UK Christine (Chris) Fox, VP and general manager UK and Ireland at Amgen, two months into her first country manager position and first time in a role outside of North America, discusses the creation of new, innovative partnership models with stakeholders across the healthcare spectrum, how Amgen is leveraging its biologic…

Spain The managing director of the Spanish affiliate of one of France’s most exciting and ambitious mid-caps speaks out about crafting a commercial powerhouse and efficient launch machine in oncology, and shares the secrets of deftly managing organizational change.    How would you describe Ipsen´s legacy and footprint within the Spanish…

China Dr. Lu Xianping is the founder and now Chairman and CEO of one of China’s few truly innovative biotech companies, ChipScreen BioSciences Co. In this exciting interview, he shares the long journey towards the commercialization of their first cancer drug, Chidamide, launched in China in 2015, ad now awaiting market…

Portugal Alnylam, pioneers in the RNA interference field, seek to bring their revolutionary medicine across Europe, and in particular Portugal before 2020. In this interview the new General Manager for Spain and Portugal, Alicia Folgueira Lopez, a rare diseases authority, discusses how to build an affiliate from scratch, the synergies across…

Spain Spanish biotech ALGENEX is using insect pupae to develop high-purity vaccines more quickly and at a lower cost than conventional production methods. Having secured further investment from outside of Spain, ALGENEX is now looking to produce its first vaccine for European regulators using insect-based production methods. We realised the huge…